]>
IRCT2017010631252N3 IRCT 2017-03-02 Qom University of Medical Sciences Effect of Atorvastatin on liver function in patients with chronic hepatitis B Investigation the effect of adding Atorvastatin to routine Tenofovir treatment on severity of liver fibrosis and liver function among patients with chronic hepatitis B 2017-02-19 anticipated 80 Complete https://irct.ir/trial/24630 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 chronic hepatitis. Intervention 1: In intervention group, Atorvastatin tablet, 20 mg, oral, once daily, for six months. Intervention 2: In control group, Atorvastatin placebo, oral, once daily, for six months.
public Mahdi Jahangiry
Gastroenterology and Hepatology Disease Research Center, Endoscopy Unit, Shahid Beheshti Hospital Qom, Shahid Beheshti Blv
Qom Iran (Islamic Republic of) 3719964797 +98 25 3612 2053 mahdijahangiry@yahoo.com; hormatia@yahoo.com Qom University of Medical Sciences scientific Ahmad Hormati
Gastroenterology and Hepatology Disease Research Center, Endoscopy Unit, Shahid Beheshti Hospital Qom, Shahid Beheshti Blv
Qom Iran (Islamic Republic of) 3719964797 +98 25 3612 2053 hormatia@yahoo.com; hormatia@muq.ac.ir Qom University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Patients between 18 and 75 years old with chronic hepatitis B for more than 6 months and dysfunction in liver function, serum LDL more than 90 mg/dl Exclusion criteria: Patients with hepatitis B less than 6 months, Inactive carriers of hepatitis B, Patients with no fibrosis and cirrhosis, Patients with decompensated cirrhosis, Patients with chronic liver disease such as willson and hemochromatosis, Patients with hepatic cell carcinoma, Patients with other malignancies, Patients with co-infection and superinfection of HIV ,HCV or HDV, Patients that were treated with Atorvastatin, Pregnant and lactating women, Increasing of liver enzymes 2 times of normal range after 1 months of treatment. 18 years 75 years Both K73.0 Chronic persistent hepatitis Treatment - Drugs Placebo In intervention group, Atorvastatin tablet, 20 mg, oral, once daily, for six months In control group, Atorvastatin placebo, oral, once daily, for six months Sevirity of fibrosis. Timepoint: Six months after begining intervention. Method of measurement: kpa with fibroscan. Liver function. Timepoint: Six months after intervention. Method of measurement: Child score. Liver enzymes levels. Timepoint: Six month after begining of intervention. Method of measurement: Blood levels with IU/ml. Qom University of Medical Sciences Approved 2017-01-14 Oom University of Medical Sciences Oom University of Medical Sciences, Saheli street, Qom Qom Iran (Islamic Republic of)